Atara Biotherapeutics, Inc.
ATRA
$9.91
-$0.32-3.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -96.72% | -88.41% | -6.33% | 51.27% | 202.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.72% | -88.41% | -6.33% | 51.27% | 202.41% |
| Cost of Revenue | -95.31% | -92.69% | -67.64% | -60.35% | -36.28% |
| Gross Profit | -99.18% | -75.27% | 367.76% | 200.60% | 154.50% |
| SG&A Expenses | -60.66% | -56.23% | -39.30% | -25.63% | -13.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -86.66% | -84.80% | -63.09% | -47.99% | -26.28% |
| Operating Income | -184.57% | -139.53% | 156.52% | 131.48% | 111.58% |
| Income Before Tax | -389.12% | 39.81% | 138.31% | 117.58% | 103.18% |
| Income Tax Expenses | 187.88% | 186.11% | 358.33% | -33.33% | -306.25% |
| Earnings from Continuing Operations | -387.97% | 39.47% | 138.28% | 117.57% | 103.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -387.97% | 39.47% | 138.28% | 117.57% | 103.20% |
| EBIT | -184.57% | -139.53% | 156.52% | 131.48% | 111.58% |
| EBITDA | -161.69% | -370.39% | 165.10% | 135.95% | 114.89% |
| EPS Basic | -201.25% | 81.95% | 124.56% | 108.67% | 99.00% |
| Normalized Basic EPS | -310.13% | 72.33% | 133.30% | 114.06% | 101.75% |
| EPS Diluted | -175.45% | 81.88% | 124.24% | 108.51% | 98.90% |
| Normalized Diluted EPS | -323.60% | 72.59% | 132.97% | 113.90% | 101.64% |
| Average Basic Shares Outstanding | 36.86% | 52.39% | 67.48% | 100.51% | 102.17% |
| Average Diluted Shares Outstanding | 36.20% | 52.33% | 68.15% | 101.36% | 103.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |